miridesap
Small moleculeexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2011 (NCT01323985)
Timeline
Indications
Studied for
Mechanism of action
- Serum amyloid P-componentBLOCKER
APCS blocker
- Serum amyloid P-componentCROSS-LINKING AGENT
Serum amyloid P-component cross-linking agent
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(=O)O- Mol. weight
- 340.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL25263 ↗
Also known as
- 1,1'-hexanedioyldi-d-proline
- 1,1'-hexanedioyldi-d-proline
- cphpc
- cphpc
- cphpc
- gsk2315698
- gsk2315698
- miridesap
- miridesap
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03044353 | Phase 2 | Jun 20, 2017 | GlaxoSmithKline |
| NCT02953808 | Phase 1 | Nov 1, 2016 | GlaxoSmithKline |
| NCT02425241 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2013 | GlaxoSmithKline, Medical Research Council, University of London, University of Oxford |
| NCT01777243 | Phase 1 | May 13, 2013 | GlaxoSmithKline, IQVIA, University of London |
| NCT01406314 | Phase 1 | Oct 13, 2011 | GlaxoSmithKline |
| NCT01323985 | Phase 1 | Jan 1, 2011 | GlaxoSmithKline |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 6 | 5 | 2 | 2011 |
| University of London | Academic/Hospital | 2 | 1 | 2 | 2013 |
| IQVIA | For profit | 1 | 0 | 1 | 2013 |
| Medical Research Council | Government | 1 | 0 | 1 | 2013 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2013 |
5 organizations
Page 1 / 1